Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade
- 27 May 2021
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 51 (8) , 902-908
Abstract
Aim: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy. However, the characteristics and prognosis of ICC is not well known. This study aims to reveal the relationship between liver function and prognosis of ICC.Methods: A total of 83 ICC patients were recruited retrospectively from March 2009 to August 2020. Child–Pugh (CP) and albumin–bilirubin (ALBI) scores were used to assess liver function. The extent of portal vein tumor thrombosis (PVTT) was classified from Vp0 to Vp4. The end‐point for this analysis was overall survival (OS).Results: The median age was 72 (44–88) years, 48 patients were male (57.8%), and 70 patients were classified as CP grade A (84.3%). At baseline, chronic liver disease (hepatitis B, 9.6%; hepatitis C, 15.7%; alcoholic liver disease, 9.6%; and nonalcoholic fatty liver disease, 4.8%) were diagnosed. The median OS of all ICC patients was 21.2 months. A total of 27 patients underwent surgical resection; these patients showed a longer median OS compared to those who did not undergo surgery (50.8 months vs. 5.5 months, p < 0.001). The prognosis of patients with ICC can be stratified by ALBI grade (grade 1, 54.3 months; grade 2a, 8.4 months; grade 2b, 3.9 months; and grade 3, 1.4 months; p < 0.001) and the extent of PVTT (Vp0, 54.3 months; Vp1/2, 8.4 months; and Vp3/4, 3.9 months; p = 0.0039).Conclusion: In this study, viral hepatitis (25.3%) was identified as the most prevalent background liver disease of ICC. Assessing liver function using ALBI grade is useful for stratifying the prognosis of patients with ICC.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP20fk0210067h0001)
This publication has 21 references indexed in Scilit:
- Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosisHepatology Research, 2020
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2020
- Current standards and future perspectives in adjuvant treatment for biliary tract cancersCancer Treatment Reviews, 2020
- Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).Journal of Clinical Oncology, 2019
- Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of JapanCancer, 2015
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinomaJournal of Hepatology, 2014
- Clinical diagnosis and management of intrahepatic cholangiocarcinomaClinical Liver Disease, 2014
- Pathogenesis, Diagnosis, and Management of CholangiocarcinomaGastroenterology, 2013
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010